Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.19 USD | +6.57% | -2.98% | +63.52% |
May. 02 | Baird Starts Spyre Therapeutics With Outperform Rating, $50 Price Target | MT |
Apr. 19 | Sector Update: Health Care Stocks Steady Pre-Bell Friday | MT |
Financials (USD)
Sales 2024 * | 5.84M | Sales 2025 * | 4.43M | Capitalization | 1.33B |
---|---|---|---|---|---|
Net income 2024 * | -172M | Net income 2025 * | -182M | EV / Sales 2024 * | 118 x |
Net cash position 2024 * | 638M | Net cash position 2025 * | 333M | EV / Sales 2025 * | 225 x |
P/E ratio 2024 * |
-8.97
x | P/E ratio 2025 * |
-10
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.42% |
Latest transcript on Spyre Therapeutics, Inc.
1 day | +6.57% | ||
1 week | -2.98% | ||
Current month | +6.54% | ||
1 month | -10.18% | ||
3 months | +46.93% | ||
6 months | +271.59% | ||
Current year | +63.52% |
Managers | Title | Age | Since |
---|---|---|---|
Cameron Turtle
CEO | Chief Executive Officer | 34 | 23-06-21 |
Scott Burrows
DFI | Director of Finance/CFO | 47 | 23-08-31 |
Brian Connolly
CTO | Chief Tech/Sci/R&D Officer | - | Nov. 26 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tomas Kiselak
BRD | Director/Board Member | 38 | 23-06-21 |
Russell Cox
CHM | Chairman | 60 | 15-05-31 |
Jeffrey Albers
BRD | Director/Board Member | 52 | Nov. 26 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 33.02 | -3.56% | 245,077 |
24-05-07 | 34.24 | -4.28% | 186,999 |
24-05-06 | 35.77 | -0.03% | 208,175 |
24-05-03 | 35.78 | -1.35% | 196,820 |
24-05-02 | 36.27 | +7.09% | 389,590 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.52% | 1.33B | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- SYRE Stock